LONDON--(BUSINESS WIRE)--Technavio has announced their latest drug pipeline analysis report on spinocerebellar ataxia. The report includes a detailed analysis of the pipeline molecules under ...

Reata Pharmaceuticals has done its homework in responding to the FDA’s concerns about an application for its nerve disorder drug. But now the biotech has to sit tight for an extra three months while ...

According to DelveInsight's analysis, the market size for Friedreich's ataxia is anticipated to surge at a significant rate by 2034. The prevalence of Friedreich's ataxia in the United States has been ...

DelveInsight's“ Friedreich's Ataxia Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Friedreich's Ataxia pipeline landscape. It covers ...

Truist has initiated coverage of Larimar Therapeutics (NASDAQ:LRMR) with a buy rating, citing an "asymmetric" risk/reward ahead of regulatory updates for its drug candidate nomla for Friedreich’s ...

The major depressive disorder failure for BHV-7000 is the drug's second, after Biohaven’s spinocerebellar ataxia treatment ...

Shares of a small biotech company skyrocketed Tuesday following the release of positive data from its registration-directed Phase II study of a fatal genetic disorder that causes muscle weakness.

Credit: Shutterstock. Elamipretide has been shown to improve frataxin levels in Friedreich ataxia patient-derived cells, and improve motor and cardiac function in an animal model of Friedreich ataxia.

University of Utah scientists found that antisense drugs reversed symptoms in mouse models of ataxia and amyotrophic lateral sclerosis. Ataxia, a rare neurodegenerative disease characterized by a lack ...

LAS VEGAS, June 5, 2025 /PRNewswire/ -- DelveInsight's Friedreich's Ataxia Market Insights report includes a comprehensive understanding of current treatment practices, Friedreich's ataxia emerging ...

The dynamics of the Friedreich's ataxia market are anticipated to change as companies across the globe are thoroughly working toward the development of new drug therapy options to treat this disease.